United Therapeutics (NASDAQ:UTHR) Price Target Increased to $121.00 by Analysts at Credit Suisse Group

United Therapeutics (NASDAQ:UTHR) had its price target increased by Credit Suisse Group from $113.00 to $121.00 in a research report sent to investors on Thursday morning, The Fly reports. They currently have an outperform rating on the biotechnology company’s stock.

UTHR has been the subject of several other research reports. BidaskClub upgraded shares of United Therapeutics from a sell rating to a hold rating in a research report on Thursday, January 30th. JPMorgan Chase & Co. upgraded shares of United Therapeutics from a neutral rating to an overweight rating and lifted their price target for the stock from $116.00 to $120.00 in a research report on Friday, January 31st. ValuEngine cut shares of United Therapeutics from a buy rating to a hold rating in a research report on Tuesday, February 4th. Zacks Investment Research cut shares of United Therapeutics from a hold rating to a sell rating and set a $93.00 price target for the company. in a research report on Thursday, January 2nd. Finally, HC Wainwright restated a hold rating and set a $85.00 price objective on shares of United Therapeutics in a report on Friday, November 1st. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $116.17.

Shares of NASDAQ UTHR traded up $0.20 during trading on Thursday, reaching $104.19. The company had a trading volume of 233,583 shares, compared to its average volume of 453,274. United Therapeutics has a 52 week low of $74.31 and a 52 week high of $128.94. The stock has a market cap of $4.56 billion, a PE ratio of -48.01, a PEG ratio of -1.57 and a beta of 1.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.91 and a current ratio of 4.11. The business’s 50 day moving average price is $92.51 and its 200-day moving average price is $87.07.

Several hedge funds have recently added to or reduced their stakes in UTHR. Great Point Partners LLC acquired a new position in shares of United Therapeutics in the third quarter valued at about $37,483,000. Renaissance Technologies LLC grew its stake in shares of United Therapeutics by 10.3% in the fourth quarter. Renaissance Technologies LLC now owns 3,544,433 shares of the biotechnology company’s stock valued at $312,194,000 after acquiring an additional 332,155 shares in the last quarter. AJO LP acquired a new position in shares of United Therapeutics in the fourth quarter valued at about $20,146,000. FMR LLC grew its stake in shares of United Therapeutics by 9.2% in the fourth quarter. FMR LLC now owns 2,383,549 shares of the biotechnology company’s stock valued at $209,943,000 after acquiring an additional 201,569 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of United Therapeutics by 39.4% in the third quarter. Point72 Asset Management L.P. now owns 640,243 shares of the biotechnology company’s stock valued at $51,059,000 after acquiring an additional 180,803 shares in the last quarter. Institutional investors and hedge funds own 93.26% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Article: What is a stock portfolio tracker?

The Fly

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.